Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Current Liabilities (2016 - 2026)

Ocular Therapeutix has reported Total Current Liabilities over the past 14 years, most recently at $47.7 million for Q1 2026.

  • For Q1 2026, Total Current Liabilities rose 25.73% year-over-year to $47.7 million; the TTM value through Mar 2026 reached $47.7 million, up 25.73%, while the annual FY2025 figure was $50.8 million, 22.86% up from the prior year.
  • Total Current Liabilities for Q1 2026 was $47.7 million at Ocular Therapeutix, down from $50.8 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $50.8 million in Q4 2025 and troughed at $24.0 million in Q1 2022.
  • A 5-year average of $35.5 million and a median of $34.9 million in 2023 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: fell 18.23% in 2024 and later soared 56.09% in 2025.
  • Year by year, Total Current Liabilities stood at $31.4 million in 2022, then increased by 11.15% to $34.9 million in 2023, then rose by 18.51% to $41.4 million in 2024, then rose by 22.86% to $50.8 million in 2025, then dropped by 6.15% to $47.7 million in 2026.
  • Business Quant data shows Total Current Liabilities for OCUL at $47.7 million in Q1 2026, $50.8 million in Q4 2025, and $49.3 million in Q3 2025.